MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.
Hypoparathyroidism is a rare condition in which the parathyroid glands in the neck produce too little parathyroid hormone (PTH), leading to low blood calcium (hypocalcemia) and high phosphorus levels.
The data highlighted sustained disease control and continued progress toward a Phase 3 program.
The company said the latest findings support the potential of canvuparatide as a once-weekly treatment designed to restore physiologic parathyroid hormone (PTH) activity while reducing treatment burden for patients.
Read Next
